Switch theme
Sign up to access all valuation multiples
Fluicell AB is a provider of high resolution SINGLE-CELL DISCOVERY PLATFORMS for biomedicine, drug development, and bioprinting. The company's products include Biopen, Dynaflow.
2012
12
Last FY Revenue $0.2M
Last FY EBITDA -$1.6M
-$1.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Fluicell achieved revenue of $0.2M and an EBITDA of -$1.6M.
Fluicell expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fluicell valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.2M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.4M | XXX | XXX | XXX |
| Gross Margin | XXX | 202% | XXX | XXX | XXX |
| EBITDA | XXX | -$1.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -806% | XXX | XXX | XXX |
| EBIT | XXX | -$1.7M | XXX | XXX | XXX |
| EBIT Margin | XXX | -852% | XXX | XXX | XXX |
| Net Profit | XXX | -$1.6M | XXX | XXX | XXX |
| Net Margin | XXX | -834% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Fluicell's stock price is SEK 8 (or $1).
Fluicell has current market cap of SEK 11.0M (or $1.1M), and EV of -SEK 10.7M (or -$1.1M).
See Fluicell trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$1.1M | $1.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Fluicell has market cap of $1.1M and EV of -$1.1M.
Fluicell's trades at -5.8x EV/Revenue multiple, and 0.7x EV/EBITDA.
Equity research analysts estimate Fluicell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fluicell's P/E ratio is not available.
See valuation multiples for Fluicell and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.1M | XXX | $1.1M | XXX | XXX | XXX |
| EV (current) | -$1.1M | XXX | -$1.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | -5.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 0.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFluicell's revenue per employee in the last FY averaged $16K, while opex per employee averaged $0.2M for the same period.
Fluicell's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fluicell's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Fluicell and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -806% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $16K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1054% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fluicell acquired XXX companies to date.
Last acquisition by Fluicell was XXXXXXXX, XXXXX XXXXX XXXXXX . Fluicell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fluicell founded? | Fluicell was founded in 2012. |
| Where is Fluicell headquartered? | Fluicell is headquartered in Sweden. |
| How many employees does Fluicell have? | As of today, Fluicell has 12 employees. |
| Is Fluicell publicy listed? | Yes, Fluicell is a public company listed on STO. |
| What is the stock symbol of Fluicell? | Fluicell trades under FLUI ticker. |
| When did Fluicell go public? | Fluicell went public in 2018. |
| Who are competitors of Fluicell? | Similar companies to Fluicell include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Fluicell? | Fluicell's current market cap is $1.1M |
| Is Fluicell profitable? | Yes, Fluicell is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
